Strengthening pharmacovigilance in South Africa

South African Medical Journal

Volumn 104, Issue 2, 2014, Pages 104-106

  Mehta, U ^a   Dheda, M ^b   Steel, G ^c   Blockman, M ^a   Ntilivamunda, A ^d   Maartens, G ^a   Pillay, Y ^e   Cohen, K ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^c NDoH   (South Africa)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e TB and Maternal and Child Health   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; FLUCONAZOLE; NEVIRAPINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DECISION MAKING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INTERPERSONAL COMMUNICATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PREGNANCY; PUBLIC HEALTH;

CONGRESSES AS TOPIC; HUMANS; NATIONAL HEALTH PROGRAMS; PHARMACOVIGILANCE; SOUTH AFRICA;

EID: 84893079689     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7517     Document Type: Article

References (10)

1. WHO Collaborating Centre for International Drug Monitoring. The Importance of Pharmacovigilance. UK: WHO, 2002. http://apps.who.int/medicinedocs/en/d/Js4893e/ (accessed 3 December 2013).
2. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007;45(2):254-260. [http://dx.doi.org/10.1086/518976]
3. Geddes R, Knight S, Moosa MYS, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006;96(8):722-724.
4. Boulle A, Orrell C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007;12(5):753-760.
5. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009;48(11):1617-1623. [http://dx.doi.org/10.1086/598977]
6. Perez EH, Dawood H, Chetty U, Esterhuizen TM, Bizaare M. Validation of the Accutrend lactate meter for hyperlactatemia screening during antiretroviral therapy in a resource-poor setting. Int J Infect Dis 2008;12(5):553-556. [http://dx.doi.org/10.1016/j.ijid.2008.03.007]
7. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: A cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc 2012;15:13. [http://dx.doi.org/10.1186/1758-2652-15-13]
8. Schutz C, Boulle A, Stead D, Rebe, Osler M, Meintjies G. Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: A retrospective observational study. AIDS Res Ther 2010;7:13. [http://dx.doi.org/10.1186/1742-6405-7-13]
9. World Health Organization. A Practical Handbook on the Pharmacovigilance of Antiretroviral Medicines. Geneva: WHO, 2009. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/ HIVhandbook.pdf (accessed 3 December 2013).
10. Mehta U, Clerk C, Allen E, et al. Protocol for a drugs exposure pregnancy registry for implementation in resource limited settings. BMC Pregnancy Childbirth 2012;12:89. [http://dx.doi.org/10.1186/1471- 2393-12-89]